![Pascal Deschaseaux](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ursprung des Netzwerks ersten Grades von Pascal Deschaseaux
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
Pharmaxon SAS
![]() Pharmaxon SAS Pharmaceuticals: MajorHealth Technology Despite recent advances in diagnostics, imaging, medical devices and surgical procedures, there has been limited progress in pharmacological treatments for a number of neurological and neuro-oncological pathologies. For pathologies like central and peripheral nervous system injuries, degenerative diseases and tumours of the nervous system, the unmet medical needs are countless and there is growing expectation from the medical community, the patients and their relatives to benefit from clinically proven solutions in the future that will save and/or improve the lives of many. The limited efficacy of approved therapies for some of these pathologies and the orphan nature of others has prompted the urgent need for new researches and therapeutic strategies. At Pharmaxon, as the pioneers of a novel pharmacological approach based on cell mobility modulation, the firm is developing the future 'control keys' for improving the nervous system's endogenous regeneration, modulating neuronal networks plasticity, and inhibiting the processes which underlie tumour cell proliferation and migration. This is obtained by modulating the activity of specific adhesion molecules implicated in cell migration, cell adhesion and cell growth. Based on such a targeted strategy, Pharmaxon is opening up new avenues for the medical management of some serious, poorly-treated, neurology and neuro-oncology pathologies. To date, this has led to three R&D programs which have reached proof-of-principle, confirming the therapeutic potential of this innovative approach, in clinic stage by 2008.
7
| Extinct | Pharmaceuticals: Major | 7 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Pascal Deschaseaux
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
MERCK & CO., INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Beckman Coulter, Inc.
![]() Beckman Coulter, Inc. Medical SpecialtiesHealth Technology Beckman Coulter, Inc. manufactures and distributes biomedical testing instrument systems and general biomedical research products. It develops and markets products that simplify, automate and innovate complex biomedical testing. The firm’s systems operate in both diagnostics and life sciences laboratories on seven continents. Its products improve the productivity of medical professionals and scientists, supplying critical information for improving patient health and delivering trusted solutions for research and discovery. The company was founded in 1935 by Arnold O. Beckman and is headquartered in Brea, CA. | Medical Specialties | Corporate Officer/Principal | |
CARA THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Tillotts Pharma AG
![]() Tillotts Pharma AG Pharmaceuticals: MajorHealth Technology Tillotts Pharma AG manufactures pharmaceuticals for treatment of gastrointestinal diseases. The firm specializes in the therapy of the lower gastrointestinal tract. It offers Asacol, Entocort, Colpermin, Tillhepo and VistaPrep. The company was founded in 1986 and is headquartered in Ziefen, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Rhone Poulenc Rorer
![]() Rhone Poulenc Rorer Chemicals: SpecialtyProcess Industries Part of Solvay SA, Rhone Poulenc Rorer is a French pharmaceutical company that manufactures and distributes pharmaceutical products. | Chemicals: Specialty | Corporate Officer/Principal | |
Pierre Fabre Médicament SAS
![]() Pierre Fabre Médicament SAS Pharmaceuticals: OtherHealth Technology Pierre Fabre Médicament SA manufactures cosmetics and pharmaceutical products. It focuses on research, development, and prescription of medicines and cosmetics. The company was founded on December 31, 1982 and is headquartered in Boulogne-Billancourt, France. | Pharmaceuticals: Other | Corporate Officer/Principal | |
Ecole Nationale des Ponts et Chaussées | College/University | Masters Business Admin | |
Amersham Health | Corporate Officer/Principal | ||
Haemostatix Ltd.
![]() Haemostatix Ltd. Pharmaceuticals: MajorHealth Technology Haemostatix Ltd. designs and develops solutions for haemostasis and thrombosis. Its products include Rapid and effective haemostatic action which is new class of topical coagulant or haemostat that is applied directly to a wound during surgery to control bleeding, and ready-to-use formulations, blood-free ingredients and a new class with a unique mode of action. The company was founded by Sarah Middleton and Alison Goodall in 2003 and is headquartered in Nottingham, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Esperante Ltd.
![]() Esperante Ltd. Investment ManagersFinance Esperante Ltd. operates as a venture investment company controlled by C&P Group Holdings. The company was founded on April 29, 1986 and is headquartered in Maidenhead, the United Kingdom. | Investment Managers | Chief Executive Officer | |
Esperante BV
![]() Esperante BV Investment ManagersFinance Esperante BV (Esperante) is a Dutch based venture capital firm which was founded by Dean Slagel in 2004. Esperante is a seed investor which invests in emerging biotechnology companies engaged in the development of novel therapeutics in areas of major unmet medical need. The firm has a portfolio of investments across France, the UK and the US. The firm provides investee companies with extended management resources, particularly in business development, as a complement to their financial contribution. They also conduct scientific and intellectual property evaluations using confidential life science industry consultants. | Investment Managers | Chief Executive Officer | |
QIAGEN MARSEILLE | Miscellaneous Commercial Services | Founder | |
Proxipaca Finance SA
![]() Proxipaca Finance SA Investment ManagersFinance Proxipaca Finance SA is a holding French company. The private company is based in Marseille, France. and has subsidiaries in France. The CEO of the company is Cyril Rocher. | Investment Managers | Chief Executive Officer | |
Primaveris SAS
![]() Primaveris SAS Investment ManagersFinance PRIMAVERIS SAS (PRIMAVERIS) is the venture capital subsidiary of Proxipaca Finance SA in France. The firm was created in 2001 under the leadership of the Provence Alpes Cote d'Azur region, the Caisse d'Epargne Provence Alpes Corse and the Caisse des Dépôts et Consignations. Based in Marseille, PRIMAVERIS specializes in financing the creation of technology companies in the Provence/Alpes/Cote d'Azur region. The firm has partnerships with three incubators in the region, IMPULSE, l'Incubateur PACA-EST and INCUBATEUR Multimédia Belle-de-Mai. | Investment Managers | President Private Equity Investor | |
Proencia SA
![]() Proencia SA Investment ManagersFinance PROENCIA SA (PROENCIA) is the Marseille-based venture capital subsidiary of Proxipaca Finance SA in France. The firm was created in 2001 when the Provence/Alpes/Cote d'Azur region, the Caisse d'Epargne Provence/Alpes/Corse and the Caisse des Dépôts et Consignations agreed to establish PROENCIA to assist very small businesses in creation, development or recovery stage. | Investment Managers | President | |
Canbex Therapeutics Ltd.
![]() Canbex Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Canbex Therapeutics Ltd. engages in the development of novel peripherally-acting cannabinoid agonists and mimetics for the treatment of multiple sclerosis spasticity and pain. Its lead drug candidate, VSN 16, has been established as a potent, stable and orally-available agonist of GPR-55 with a clear anti-spasticity effect in a validated preclinical model. The company was founded by David Baker, Gavin Giovannoni, Cristina Visintin, Gareth Pryce and David Lawrence Selwood in 2005 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Arquer Diagnostics Ltd.
![]() Arquer Diagnostics Ltd. Medical/Nursing ServicesHealth Services Arquer Diagnostics Ltd. develops proprietary diagnostic immunoassays for the detection of prostate and bladder cancer using urine samples. Its develops non-invasive, urine-based ELISA and Point-of Care tests meet the increased demand for cost-effective healthcare technologies that not only enhance patient care but help to reduce overall healthcare costs by improving patient outcomes. The firm will commercialise ELISA and point-of-care urine tests for prostate and bladder cancer for use in the urology clinic, hospital lab and the GP’s surgery. The company was founded by David Nicholas Miller-Jones and William Dawson in 2007 and is headquartered in Sunderland, the United Kingdom. | Medical/Nursing Services | Director/Board Member | |
Ipsogen, Inc.
![]() Ipsogen, Inc. Medical/Nursing ServicesHealth Services Part of QIAGEN NV, Ipsogen, Inc. is a company that develops and markets molecular diagnostic tests for leukemia and breast cancer. The company is based in Stamford, CT. The company was founded by Vincent Fert. | Medical/Nursing Services | Director/Board Member | |
Centrale Marseille | College/University | Undergraduate Degree | |
Esperante AB | Chief Executive Officer | ||
Ferring Pharmaceuticals Ltd.
![]() Ferring Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Ferring Pharmaceuticals Ltd. manufactures and produces pharmaceutical products. It offers Zomacton (somatropin) for that treatment of growth failure in children and for girl’s diagnosed with Turners syndrome; GONAPEPTYL (triptorelin), a GnRH agonist that is used for the treatment of children with central precocious puberty; Testim (testosterone gel), a hydroalcoholic topical gel; and PENTASA (mesalazine), which is used for the treatment of inflammatory bowel diseases. The company was founded in 1975 and is headquartered in Middlesex, the United Kingdom. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Oxford Cancer Biomarkers Ltd.
![]() Oxford Cancer Biomarkers Ltd. Hospital/Nursing ManagementHealth Services Oxford Cancer Biomarkers Ltd. provides cancer treatment services. It offers a suite of drug-specific companion diagnostic kits that allow the biomarker to be directly measured in tumor biopsies or patient DNA and thereby patients that respond favorably to the drug identified. The company was founded by David Kerr and Nick LaThangue in 2012 and is headquartered in Oxford, the United Kingdom. | Hospital/Nursing Management | Director/Board Member | |
HalioDxinvest SAS
![]() HalioDxinvest SAS BiotechnologyHealth Technology HalioDxinvest SAS develops and researches biotechnology products. The company was incorporated on October 17, 2014 and is headquartered in Marseille, France. | Biotechnology | Founder | |
Altacor Ltd.
![]() Altacor Ltd. Pharmaceuticals: MajorHealth Technology Altacor Ltd. operates as a specialist ophthalmology company develops and markets a portfolio of products in the fields of dry eye, glaucoma and ocular infection. The company was founded by Francesca Elizabeth Crawford and David Francis Alcraft in 2007 and is headquartered in Theale, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member |
Statistik
International
Frankreich | 12 |
Vereinigtes Königreich | 12 |
Vereinigte Staaten | 8 |
Schweiz | 2 |
Israel | 2 |
Sektoral
Health Technology | 16 |
Finance | 7 |
Health Services | 4 |
Consumer Services | 3 |
Commercial Services | 3 |
Operativ
Director/Board Member | 19 |
Corporate Officer/Principal | 12 |
Chief Executive Officer | 5 |
Founder | 4 |
President | 3 |
Am stärksten vernetzte Beziehungen
- Börse
- Insiders
- Pascal Deschaseaux
- Unternehmensverbindungen